Biora Therapeutics Earnings Call Transcripts
Fiscal Year 2024
-
Two innovative drug-device platforms were highlighted: NaviCap, which showed strong phase I results for targeted ulcerative colitis therapy, and BioJet, advancing needle-free biologic delivery with active pharma partnering discussions. Both programs are positioned for significant near-term milestones.
-
Two proprietary platforms enable targeted and systemic oral drug delivery, with NaviCap showing strong phase I results in UC and BioJet advancing through major pharma collaborations. Next steps include a larger UC trial and anticipated BioJet partnerships.
-
Q2 2024 saw successful Phase 1 results for BT-600, strong progress with BioJet, and a $16M capital raise. BioJet achieved ~40% bioavailability, and partnership talks with major pharma are nearing completion. Clinical trials and manufacturing scale-up are on track.
-
Phase I results for BT-600 using the NaviCap platform showed precise, pancolonic delivery of tofacitinib with significantly reduced systemic exposure and strong safety in healthy volunteers. These findings support further clinical development in ulcerative colitis patients.